1. Volume 146, Issue 4, Pages 941-949.e2 (April 2014)
Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease 
Mark T. Osterman, William J. Sandborn, Jean-Frederic Colombel, Anne M. Robinson, Winnie Lau, Bidan Huang, Paul F. Pollack, Roopal B. Thakkar, James D. Lewis 
Gastroenterology 
Volume 146, Issue 4, Pages e2 (April 2014)
DOI: /j.gastro
Copyright © 2014 AGA Institute Terms and Conditions

2. Figure 1
(A) Risk of malignancies excluding NMSC with adalimumab (ADA) monotherapy or combination therapy compared with the general population. (B) Risk of NMSC with ADA monotherapy or combination therapy compared with the general population. IMM, immunomodulator.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions